Chimeric Dengue 2 PDK-53/West Nile NY99 Viruses Retain the Phenotypic Attenuation Markers of the Candidate PDK-53 Vaccine Virus and Protect Mice against Lethal Challenge with West Nile Virus
Open Access
- 15 June 2005
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 79 (12) , 7300-7310
- https://doi.org/10.1128/jvi.79.12.7300-7310.2005
Abstract
Chimeric dengue serotype 2/West Nile (D2/WN) viruses expressing prM-E of WN NY99 virus in the genetic background of wild-type D2 16681 virus and two candidate D2 PDK-53 vaccine variants (PDK53-E and PDK53-V) were engineered. The viability of the D2/WN viruses required incorporation of the WN virus-specific signal sequence for prM. Introduction of two mutations at M-58 and E-191 in the chimeric cDNA clones further improved the viability of the chimeras constructed in all three D2 carriers. Two D2/WN chimeras (D2/WN-E2 and -V2) engineered in the backbone of the PDK53-E and -V viruses retained all of the PDK-53 vaccine characteristic phenotypic markers of attenuation and were immunogenic in mice and protected mice from a high-dose 107 PFU challenge with wild-type WN NY99 virus. This report further supports application of the genetic background of the D2 PDK-53 virus as a carrier for development of live-attenuated, chimeric flavivirus vaccines in general and the development of a chimeric D2/WN vaccine virus against WN disease in particular.Keywords
This publication has 60 references indexed in Scilit:
- ChimeriVax-West Nile Virus Live-Attenuated Vaccine: Preclinical Evaluation of Safety, Immunogenicity, and EfficacyJournal of Virology, 2004
- Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine Formulations in Nonhuman PrimatesJournal of Virology, 2004
- The Epidemic of West Nile Virus in the United States, 2002Vector-Borne and Zoonotic Diseases, 2004
- Chimeric Live, Attenuated Vaccine against Japanese Encephalitis (ChimeriVax‐JE): Phase 2 Clinical Trials for Safety and Immunogenicity, Effect of Vaccine Dose and Schedule, and Memory Response to Challenge with Inactivated Japanese Encephalitis AntigenThe Journal of Infectious Diseases, 2003
- Yellow Fever Virus/Dengue-2 Virus and Yellow Fever Virus/Dengue-4 Virus Chimeras: Biological Characterization, Immunogenicity, and Protection against Dengue Encephalitis in the Mouse ModelJournal of Virology, 2003
- West Nile Encephalitis: An Emerging Disease in the United StatesClinical Infectious Diseases, 2001
- Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteersVaccine, 2001
- Chimeric Dengue Type 2 (Vaccine Strain PDK-53)/Dengue Type 1 Virus as a Potential Candidate Dengue Type 1 Virus VaccineJournal of Virology, 2000
- Origin of the West Nile Virus Responsible for an Outbreak of Encephalitis in the Northeastern United StatesScience, 1999
- Dengue Virus-Specific Memory T Cell Responses in Human Volunteers Receiving a Live Attenuated Dengue Virus Type 2 Candidate VaccineThe Journal of Infectious Diseases, 1994